From POLITICO · · 50s
Cancer drug trials have changed; value assessments must too
How clinical trials for cancer medicines have evolved, and why regulators need to account for that shift when assessing their worth.
In brief
How clinical trials for cancer medicines have evolved, and why regulators need to account for that shift when assessing their worth. Cancer medicine trials have changed significantly, requiring value assessment methods to adapt to reflect how modern trials differ from past approaches. Originally reported by POLITICO.
Cancer trials have changed shape
Clinical trials for cancer medicines have evolved significantly over time. How these trials are designed and run today differs from historical approaches to testing.
Value assessments lag behind
Regulators assess the value of cancer drugs using methods that may not reflect how modern trials work. Current assessment approaches were built on older trial designs.
Methods need updating
Value assessment frameworks must evolve to account for how cancer medicine trials have changed. Regulators should align their evaluation methods with current trial practices.
The headline
Cancer medicine trials have changed significantly, requiring value assessment methods to adapt to reflect how modern trials differ from past approaches.
